Abstract: The invention relates to vaccines for the prevention or treatment of infectious diseases, and to methods of preparing or delivering such vaccines. In particular, a vaccine for use in the prevention or treatment of disease is used in a dose of, via a parenteral route without adjuvant less than 0.03 µg antigen and with adjuvant less than 0.003 µg antigen, and via a mucosal route without adjuvant less than 1 µg antigen and/or the equivalent of 1.6 × 107 PFU and with adjuvant less than 0.04 µg antigen and/or the equivalent of 1.

Abstract: The invention relates to vaccines for the prevention or treatment of infectious diseases, and to methods of preparing or delivering such vaccines. In particular, a vaccine for use in the prevention or treatment of disease is used in a dose of, via a parenteral route without adjuvant less than 0.03 ?g antigen and with adjuvant less than 0.003 ?g antigen, and via a mucosal route without adjuvant less than 1 ?g antigen and/or the equivalent of 1.6×107 PFU and with adjuvant less than 0.04 ?g antigen and/or the equivalent of 1.

Abstract: The invention relates to a protective device such as a face mask. The device protects the user from infection and may simultaneously immunise the user against future infection. The invention particularly relates to a protective device comprising a disinfection chamber wherein the chamber is arranged to disinfect and/or sterilize fluid in the chamber prior to discharge of the fluid from the chamber such that the fluid discharged from the chamber comprises inactive microorganisms, for example a device comprising a disinfection chamber in fluid communication with a face mask and wherein the chamber is arranged to disinfect and/or sterilize fluid in the chamber prior to discharge of the fluid from the chamber to the mask such that the fluid discharged from the chamber to the mask comprises inactive microorganisms. The invention also relates to a method of use of the device.

Abstract: A protective device protects the user from infection and may simultaneously immunize the user against future infection. In an embodiment, the protective device includes a disinfection chamber wherein the chamber is arranged to disinfect and/or sterilize fluid in the chamber prior to discharge of the fluid from the chamber such that the fluid discharged from the chamber comprises inactive microorganisms. The device may include a disinfection chamber in fluid communication with a face mask, with the chamber arranged to disinfect and/or sterilize fluid in the chamber prior to discharge of the fluid from the chamber to the mask, such that the fluid discharged from the chamber to the mask comprises inactive microorganisms.

Abstract: The invention relates to a protective device such as a face mask. The device protects the user from infection and may simultaneously immunise the user against future infection. The invention particularly relates to a protective device comprising a disinfection chamber wherein the chamber is arranged to disinfect and/or sterilize fluid in the chamber prior to discharge of the fluid from the chamber such that the fluid discharged from the chamber comprises inactive microorganisms, for example a device comprising a disinfection chamber in fluid communication with a face mask and wherein the chamber is arranged to disinfect and/or sterilize fluid in the chamber prior to discharge of the fluid from the chamber to the mask such that the fluid discharged from the chamber to the mask comprises inactive microorganisms. The invention also relates to a method of use of the device.

Abstract: A cancer immunogen comprises foreign MHC molecules and additionally one or more oncognes (or constructs that will produce an antigenic region thereof) which can be used to immunize against tumors containing the same or similar oncogenes. Where pathogen-free allogeneic cells are used, it may not be necessary to kill the vaccine before it is administered. The efficacy of the vaccine may be enhanced if the cells also contain immunoenhancing molecules, tumor antigens, or third-party antigens. Cell vaccines containing oncongens can be standardized and used to treat (risk of) specific cancers where there are analogous oncongenes in the tumor or pre-cancerous cells. A panel of such cells covering different oncogenes may be used. The vaccines can be used to immunize prophylactically, in conduction with other therapy, post-surgery or on their own.